Home » Authors » Trista Morrison

Articles by Trista Morrison

Ex-Cabrellis Team Launches Tragara With $40M Series A

March 15, 2007

By Trista Morrison

Ex-Cabrellis Team Launches Tragara With $40M Series A

March 15, 2007

By Trista Morrison

Array Licenses TLR Program To VentiRx, Keeps Cancer Option

March 14, 2007

By Trista Morrison

A week after closing a $26.6 million Series A financing to acquire Toll-like receptor (TLR) assets, VentiRx Pharmaceuticals Inc. licensed a preclinical TLR program from Array BioPharma Inc. (BioWorld Today)

Array Licenses TLR Program To VentiRx, Keeps Cancer Option

March 14, 2007

By Trista Morrison

A week after closing a $26.6 million Series A financing to acquire Toll-like receptor (TLR) assets, VentiRx Pharmaceuticals Inc. licensed a preclinical TLR program from Array BioPharma Inc. (BioWorld Today)

Takeda Deal With Paradigm Expands To Acquisition

March 13, 2007

By Trista Morrison

Takeda Deal With Paradigm Expands To Acquisition

March 13, 2007

By Trista Morrison

Conference Recaps Trends, Challenges and Opportunities

March 9, 2007

By Trista Morrison

Hollis-Eden Down On HHS Rejection of Radiation Drug

March 9, 2007

By Trista Morrison

Hollis-Eden Down On HHS Rejection of Radiation Drug

March 9, 2007

By Trista Morrison

Conference Recaps Trends, Challenges and Opportunities

March 9, 2007

By Trista Morrison

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 27, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 27, 2024.
In muscular dystrophies, gene therapies race the clock
BioWorld
Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...
Bridgebio, with FDA approval, faces Pfizer in ATTR
BioWorld
With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...
‘Evo’ AI can design complete genomes
BioWorld Science
The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.